ONJ, medical cannabis and a nod to Australian cannabis stocks
I don’t usually watch 60 Minutes. I find it overproduced and overhyped these days and pine for the time when Jana Wendt and George Negus, were going toe-to-toe with people.
I was just a kid back then, but those two alone, along with Ray Martin and Ian Leslie, were part of the reason I wanted to become a journalist or writer or any part of the media industry.
I wanted to wear a tweed jacket and throw it over my shoulder and go into war zones.
I don’t remember that initial 60 Minutes team putting themselves before the story, as seems to happen a lot these days on a variety of current affairs shows, but sometimes the current crop produce a story I am interested in and last night (Sunday, 4 August) it had to do with Olivia Newton John.
Here I go being nostalgic again. As a kid in the time of 60 Minutes’ glory years, I, along with many others, hoped Newton John could be hopelessly devoted to me. I was very much pre-teen in 1978 when Grease came out, so please forgive me.
Today, as a man in his mid-to-late 40s who writes a lot about medical cannabis and related listed companies, my interest is always piqued by medical cannabis based human interest stories.
So when Liz Hayes interviewed Sandy about cannabis use, I felt it was worth repeating Newton John’s fight with stage 4 cancer and how medical cannabis helped her get through it.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.